Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc. (ALLR) is a clinical-stage biopharmaceutical company focused on developing personalized cancer therapeutics. The company combines drug candidates with its proprietary DRP® companion diagnostic platform to identify patients most likely to benefit from treatment, operating at the intersection of precision medicine and oncology.
What the company does
Allarity operates as a precision oncology company centered on the development of cancer therapeutics paired with biomarker-driven patient selection. The company’s core approach leverages its Drug Response Predictor (DRP®), a proprietary technology platform designed to predict which patients are most likely to respond to specific cancer drugs based on tumor gene expression profiling. By matching patients to drugs tailored to their cancer biology, the company aims to improve clinical trial efficiency and patient outcomes.
The company’s primary focus is the clinical development of stenoparib, an orally available small-molecule inhibitor targeting both PARP1/2 and tankyrase enzymes—signaling pathways involved in DNA repair and cancer cell survival. Stenoparib is in development for advanced ovarian cancer and other solid tumors, with development supported in part by funding from the U.S. Department of Veterans Affairs for lung cancer applications.
How it makes money
As a clinical-stage company, Allarity does not yet generate product revenue from approved therapeutics. The company’s financial sustainability depends on capital raised through equity offerings, debt financing, and research grants. Development timelines in oncology typically extend several years through clinical trial phases before potential commercialization. The company has received FDA Fast Track designation for stenoparib in advanced recurrent ovarian cancer, a status that may accelerate review and reduce development timelines.
Where it sits in its industry
Allarity competes within a large and active landscape of clinical-stage biopharmaceutical companies developing cancer drugs and diagnostic solutions. The oncology sector includes numerous competitors pursuing PARP inhibitors and companion diagnostics, ranging from early-stage startups to major pharmaceutical firms with established drug portfolios.
The DRP® platform distinguishes Allarity by combining therapeutic development with patient stratification technology, a model that has gained traction across the industry as precision medicine becomes more integral to drug approval and clinical practice. Patent protection for the stenoparib DRP® companion diagnostic extends exclusivity into 2039, providing potential durability for the diagnostic-drug combination.
The company’s dual focus on drug development and diagnostic innovation positions it in an emerging category of integrated precision oncology companies—those developing both the therapeutic and the biomarker test needed to guide treatment selection.
How to research it
Investors and researchers can access Allarity’s SEC filings—including 10-K annual reports, 10-Q quarterly reports, and 8-K current reports—through the SEC EDGAR database using CIK 1860657. These filings contain detailed discussion of clinical trial design, regulatory milestones, manufacturing progress, and financial statements.
Clinical trial status and enrollment information can be found on ClinicalTrials.gov, where Allarity’s stenoparib studies are registered. Conference presentations at major oncology meetings (such as the American Association for Cancer Research) provide peer-reviewed data on the DRP® platform and stenoparib efficacy in various cancer populations.
The company’s investor relations website and press releases announce regulatory designations, trial progression, patent grants, and financing activities—materials useful for tracking the company’s development trajectory and de-risking milestones.